Cantor Fitzgerald Predicts TVTX FY2026 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for Travere Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn $1.86 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Several other brokerages have also commented on TVTX. Guggenheim restated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research note on Monday, April 14th. Canaccord Genuity Group raised their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, April 10th. Scotiabank restated an “outperform” rating on shares of Travere Therapeutics in a research report on Friday, April 11th. Bank of America raised their price target on shares of Travere Therapeutics from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday, April 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Travere Therapeutics in a report on Friday, May 16th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $32.14.

Travere Therapeutics Stock Performance

Shares of TVTX opened at $14.94 on Wednesday. The company’s fifty day moving average is $16.87 and its 200-day moving average is $18.56. Travere Therapeutics has a 12 month low of $6.80 and a 12 month high of $25.29. The firm has a market cap of $1.33 billion, a price-to-earnings ratio of -3.64 and a beta of 0.75. The company has a quick ratio of 1.68, a current ratio of 1.71 and a debt-to-equity ratio of 24.96.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company had revenue of $81.73 million for the quarter, compared to analyst estimates of $77.44 million. During the same quarter in the prior year, the business posted ($1.76) EPS. Travere Therapeutics’s quarterly revenue was up 83.3% on a year-over-year basis.

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of TVTX. Rhumbline Advisers grew its stake in Travere Therapeutics by 2.7% during the first quarter. Rhumbline Advisers now owns 124,550 shares of the company’s stock worth $2,232,000 after buying an additional 3,302 shares in the last quarter. Polar Asset Management Partners Inc. bought a new position in Travere Therapeutics during the 1st quarter worth approximately $304,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Travere Therapeutics by 13.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after acquiring an additional 6,831 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Travere Therapeutics by 479.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,184,898 shares of the company’s stock valued at $39,153,000 after acquiring an additional 1,808,098 shares in the last quarter. Finally, PDT Partners LLC increased its stake in shares of Travere Therapeutics by 25.3% in the 1st quarter. PDT Partners LLC now owns 309,534 shares of the company’s stock valued at $5,547,000 after acquiring an additional 62,425 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Eric M. Dube sold 18,924 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the completion of the transaction, the chief executive officer now owns 419,173 shares in the company, valued at $8,823,591.65. This represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christopher R. Cline sold 1,784 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the transaction, the chief financial officer now owns 93,126 shares of the company’s stock, valued at $1,960,302.30. This trade represents a 1.88% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,527 shares of company stock valued at $473,814. Insiders own 4.19% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.